A Phase 2 interventional study of Lumacaftor 200 MG and Placebo in Heart Failure With Reduced Ejection Fraction, sponsored by Qanatpharma AG. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by Qanatpharma AG · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 224 studies in Cognitive Dysfunction with a site in Canada — 61 open to participants now, 80 under way, 7 of them phase 3. Cognitive Dysfunction · Canada.
Among the 224 studies in Cognitive Dysfunction with a site in Canada, this one is the 87th largest by planned enrollment of the 171 interventional ones that give a count, is one of 11 that started in 2026, is one of 23 in phase 2, reaches primary completion later than 46 of the 79 other live ones, and was the 202nd registered.
3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,120 are open to participants now.
Browse Cognitive Dysfunction studies →61 of the 224 studies in Cognitive Dysfunction with a site in Canada are open now. Recruiting first, the newest first:
Posit Science Corporation · Sites in Canada
Ages 65+
Laval University · Sites in Canada
Ages 60+
Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal · Sites in Canada
Ages 50+ · Healthy volunteers
University of British Columbia · Sites in Canada
Ages 50–80 · Healthy volunteers
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
224 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 29 · Phase 3 21 · Phase 4 3
First in 1999; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 64 across 2,799 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 64 across the 171 interventional studies, 353 across the 52 observational. Of the 121 that completed or were terminated, 17 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 224 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Qanatpharma AG as lead sponsor.
Qanatpharma AG has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
24 of the studies in Cognitive Dysfunction with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05230758Phase 3Donald MabbottEffect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour | 2027-11-30 |
| NCT06529744University Health Network, TorontoImproving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling | 2026-11 |
| NCT04335994Sunnybrook Health Sciences CentreENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing | 2026-12 |
| NCT06783283Centre for Addiction and Mental HealthTACS to Engage Theta-Gamma Coupling and Enhance Working Memory in Patients With MCI (tACS-MCI) | 2026-12 |
Add all 24 to your calendar (.ics) → With an account.
Among the 224 studies in Cognitive Dysfunction with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cognitive impairment (CI) is highly prevalent in patients with heart failure with reduced ejection fraction (HFrEF), which has significant implications for disease management, quality of life and clinical outcomes. Currently, there are no specific treatments for CI aside from the current standard of care therapy for HF, making this a high unmet medical need. Impaired cerebral autoregulation is a proposed mechanistic factor that leads to cerebral hypoperfusion, ischemic damage and the development for CI. Preclinical data indicates that restoring CFTR-protein expression normalizes cerebral microvascular function and cerebral blood flow (CBF) in models of HF. The purpose of this study is to investigate whether CFTR-targeting therapy enhances cerebral perfusion and cognitive function in heart failure patients using the CFTR-corrector Lumacaftor.
Recent preclinical research has identified wild-type cystic fibrosis transmembrane conductance regulator (CFTR) in cerebral artery smooth muscle cells as a key protein involved in the myogenic mechanism governing cerebrovascular reactivity and a potential therapeutic target. In experimental models of HF, CFTR-protein expression is downregulated, which is associated with increased vascular tone, reduced cerebral blood flow, increased neuronal damage and poorer scores on functional tests. Treatment with CFTR-correctors reverses the pathology and normalizes cerebral artery CFTR-expression, vascular tone, CBF, neuronal health and functional outcome. Lumacaftor is an existing small-molecule CFTR-corrector that increases the abundance of CFTR-protein at the cell membrane by augmenting its trafficking and stability. It is currently approved as part of a combination therapy (lumacaftor/ivacaftor) in cystic fibrosis patients with the CFTR F508del gene mutation.
The purpose of this trial is to build on the CFTR-stabilizing properties of lumacaftor in HF patients and determine whether clinical application of a CFTR-stabilizing treatment improves cerebral perfusion and cognitive performance. The study is a Phase II proof-of-concept, randomized, parallel group, placebo-controlled, double-blind, longitudinal, single treatment center trial of 60 stable adults with HFrEF (no hospitalization within 3 months) on optimal goal-directed medical therapy treated with lumacaftor vs. identical placebo. This will include participants who are New York Heart Association (NYHA) class II-III, with reduced cardiac output and an EF of \<40%.
Following eligibility assessment and consent procedures, participants will undergo screening to measure baseline CBF using perfusion-weighted magnetic resonance imaging (MRI). Participants enrolled in the study will be allocated 1:1 to receive lumacaftor 200 mg q12 or identical placebo for 30 days. A follow-up cerebral MRI will assess the change from baseline at 1 month in global CBF as the primary outcome measure of the trial. In additional to safety metrics, a battery of neurocognitive assessments will be administered using the Montreal Cognitive Assessment (MoCA), Trail Making Test (TMT), the Hospital Anxiety and Depression Scale (HADS) and the Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) to determine changes from baseline, at 1 month and 3 months in cognitive function, mental health, and quality of life as key secondary outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants screened for enrolment must meet all of the following criteria to be eligible for study participation:
Female participants must fulfill at least one of the following:
Exclusion criteria
Participants screened for enrolment, meeting any of the following criteria are not eligible for study participation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 1 tablet of Lumacaftor 200 mg twice daily for 30 days.
Drug: Lumacaftor 200 MG
Participants receive 1 tablet of Lumacaftor placebo tablet twice daily for 30 days.
Drug: Placebo
Lumacaftor 200 mg q12
Identical placebo
Efficacy of lumacaftor treatment in increasing cerebral blood flow versus placebo in HFrEF patients.
Change from baseline in global cerebral blood flow at 1 month using treatment or placebo as assessed by perfusion weighted MRI.
Time frame: Baseline and 1 month
Rate of treatment-emergent adverse events as assessed by MedDRA.
Number of treatment-emergent AEs by severity and treatment received. This will capture participants who received at least one dose of treatment.
Time frame: Baseline up to Day 90
Number of participants with clinically significant changes from baseline in physical examinations findings at 1 week, 1 month and 3 months.
Time frame: Baseline, 1 week, 1 month and 3 months
Number of participants with clinically significant changes from baseline in vital signs at 1 week, 1 month and 3 months.
Time frame: Baseline, 1 week, 1 month and 3 months
Number of participants with clinically significant changes from baseline in electrocardiograms (ECGs) at 1 week, 1 month and 3 months.
Time frame: Baseline, 1 week, 1 month and 3 months
Number of participants with clinically significant changes from baseline in laboratory test results at 1 week, 1 month and 3 months.
Time frame: Baseline, 1 week, 1 month and 3 months
Number of participants with clinically significant changes from baseline in the Columbia Suicide Severity Rating Scale (C-SSRS) at 1 week, 1 month and 3 months.
The C-SSRS is a questionnaire that captures severity and intensity of suicidal ideation and the number of suicidal behavioural attempts.
Time frame: Baseline, 1 week, 1 month and 3 months
Changes from baseline in Montreal Cognitive Assessment (MoCA) scores at 1 month and 3 months.
MoCA is a screening tool for global cognitive function over several domains (memory, attention, language, visuospatial skills, and executive function). Scoring is 0-30-points, with higher scores indicating better global cognition function.
Time frame: Baseline, 1 month and 3 months
Changes from baseline in the 36-Item Short Form Health Survey (SF-36) scores at 1 month and 3 months.
The SF-36 is a self-report, general measure of health status and quality of life, assessing eight domains (physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions). Scoring is 0-100 points for each domain, with higher scores indicating a more favourable health state.
Time frame: Baseline, 1 month and 3 months
Changes from baseline in the Hospital Anxiety and Depression Scale (HADS) scores at 1 month and 3 months.
HADS is a self-report, 14-item measure to screen for depression and anxiety disorders among non-psychiatric, medically ill, outpatient populations. Scoring is 7 points for each domain of depression and anxiety, with scores of less than 7 for non-cases, 8-10 for mild cases, 11-14 for moderate cases and 15-21 for severe cases.
Time frame: Baseline, 1 month and 3 months
Changes from baseline in the Trail-Making-Test (TMT) scores at 1 month and 3 months.
The TMT is an attention and task-switching, two-part test to measure executive and psychomotor function by connecting a series of dots accurately. Scoring is based on time to completion, with a score of more than 70-78 seconds deficient for TMT-A and a score of more than 180-273 seconds deficient for TMT-B.
Time frame: Baseline, 1 month and 3 months
Plan to share: Yes — Qanatpharma will provide access upon request to individual de-identified participant data reported in the publication beginning 12 months after publication and for up to 36 months following article publication. Data sharing requests can be made by qualified researchers for approved proposals under the terms of a Data Use Agreement. Contact information will be provided at the time of article publication.
Supporting information: Study protocol
Time frame: 12 months after article publication and for up to 36 months following article publication.
Access criteria: Data sharing requests can be made by qualified researchers for approved proposals under the terms of a Data Use Agreement.
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for May 2027, 10 months later.
Of 42 industry-sponsored phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 10 months is below that.
Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lumacaftor